Weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab for newly diagnosed multiple myeloma
Prof. Ola Landgren
The nonrandomized MANHATTAN trial at Memorial Sloan Kettering Cancer Center (New York, NY) found that among patients with newly diagnosed multiple myeloma, the combination of weekly carfilzomib-lenalidomide-dexamethasone-daratumumab was associated with high rates of MRD negativity (71%). ORR rate was 100% and VPGR rate was 95%. The 1-year PFS was 98% and the 1-year OS was 100%. The therapy was deemed to be well tolerated.
